272 related articles for article (PubMed ID: 18372911)
1. Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers.
Zhu Q; Youn H; Tang J; Tawfik O; Dennis K; Terranova PF; Du J; Raynal P; Thrasher JB; Li B
Oncogene; 2008 Jul; 27(33):4569-79. PubMed ID: 18372911
[TBL] [Abstract][Full Text] [Related]
2. G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells.
Liu J; Youn H; Yang J; Du N; Liu J; Liu H; Li B
Prostate; 2011 Sep; 71(12):1276-86. PubMed ID: 21308712
[TBL] [Abstract][Full Text] [Related]
3. P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.
Pang J; Yang YW; Huang Y; Yang J; Zhang H; Chen R; Dong L; Huang Y; Wang D; Liu J; Li B
Prostate; 2017 Feb; 77(3):299-308. PubMed ID: 27800642
[TBL] [Abstract][Full Text] [Related]
4. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells.
Yang L; Xie S; Jamaluddin MS; Altuwaijri S; Ni J; Kim E; Chen YT; Hu YC; Wang L; Chuang KH; Wu CT; Chang C
J Biol Chem; 2005 Sep; 280(39):33558-65. PubMed ID: 16061480
[TBL] [Abstract][Full Text] [Related]
5. Sterol regulatory element-binding protein-1c represses the transactivation of androgen receptor and androgen-dependent growth of prostatic cells.
Suh JH; Gong EY; Kim JB; Lee IK; Choi HS; Lee K
Mol Cancer Res; 2008 Feb; 6(2):314-24. PubMed ID: 18245227
[TBL] [Abstract][Full Text] [Related]
6. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.
Kasina S; Macoska JA
Mol Cell Endocrinol; 2012 Apr; 351(2):249-63. PubMed ID: 22245379
[TBL] [Abstract][Full Text] [Related]
7. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
8. A natural androgen receptor antagonist induces cellular senescence in prostate cancer cells.
Hessenkemper W; Roediger J; Bartsch S; Houtsmuller AB; van Royen ME; Petersen I; Grimm MO; Baniahmad A
Mol Endocrinol; 2014 Nov; 28(11):1831-40. PubMed ID: 25203674
[TBL] [Abstract][Full Text] [Related]
9. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T
Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566
[TBL] [Abstract][Full Text] [Related]
10. ARF represses androgen receptor transactivation in prostate cancer.
Lu W; Xie Y; Ma Y; Matusik RJ; Chen Z
Mol Endocrinol; 2013 Apr; 27(4):635-48. PubMed ID: 23449888
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
12. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
[TBL] [Abstract][Full Text] [Related]
13. The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling.
Lamb LE; Zarif JC; Miranti CK
Cancer Res; 2011 Apr; 71(7):2739-49. PubMed ID: 21310825
[TBL] [Abstract][Full Text] [Related]
14. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival.
Rokhlin OW; Taghiyev AF; Bayer KU; Bumcrot D; Koteliansk VE; Glover RA; Cohen MB
Cancer Biol Ther; 2007 May; 6(5):732-42. PubMed ID: 17387273
[TBL] [Abstract][Full Text] [Related]
15. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
16. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity.
Lyons LS; Burnstein KL
Mol Endocrinol; 2006 May; 20(5):1061-72. PubMed ID: 16384856
[TBL] [Abstract][Full Text] [Related]
17. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
[TBL] [Abstract][Full Text] [Related]
18. Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells.
Xie Y; Wolff DW; Lin MF; Tu Y
Mol Pharmacol; 2007 Jul; 72(1):73-85. PubMed ID: 17430995
[TBL] [Abstract][Full Text] [Related]
19. Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling.
D'Antonio JM; Vander Griend DJ; Antony L; Ndikuyeze G; Dalrymple SL; Koochekpour S; Isaacs JT
PLoS One; 2010 Jul; 5(7):e11475. PubMed ID: 20628607
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
